Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Author(s):  
M.G. Lebwohl ◽  
L. Stein Gold ◽  
K. Papp ◽  
G. Han ◽  
D.M. Pariser ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document